Calidi Biotherapeutics Competitors
| CLDI Stock | 0.30 0.02 7.04% |
Calidi Biotherapeutics vs Soligenix Correlation Summary
Weak diversification
For the present investment horizon, the measured correlation between Calidi Biotherapeutics and Soligenix stands at 0.59, or Weak diversification. The overlap area shows the portion of risk that can be diversified away by holding both instruments together.
Moving together with Calidi Stock
Moving against Calidi Stock
Experienced investors tracking Calidi Biotherapeutics' watch for mean reversion setups where price has deviated from its long-run average. Sentiment extremes, news events, or liquidity shocks are common catalysts for these temporary dislocations in Calidi Biotherapeutics. Prices periodically overshoot their intrinsic value in both directions, creating mean reversion opportunities in Calidi Biotherapeutics. The mean reversion signal is most useful when combined with fundamental confirmation for Calidi Biotherapeutics'.
Calidi Biotherapeutics Competition Correlation Matrix
Studying peer correlation around Calidi Biotherapeutics gives investors a cleaner read on how much independent price behavior still exists across the competitive set. The useful question is whether competitors are behaving like true alternatives or simply tracking the same sector move with different volatility.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Evaluating Calidi Stock requires separating price momentum from underlying business quality relative to competitors. Without reviewing risk-adjusted indicators, investors may overweight recent returns and underweight the volatility required to achieve them. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CMND | 5.21 | -1.75 | 0.00 | -1.31 | 0.00 | 8.04 | 42.74 | |||
| CANF | 5.31 | -0.44 | 0.00 | -1.39 | 0.00 | 10.00 | 43.99 | |||
| KZIA | 6.24 | 0.16 | 0.00 | -0.02 | 0.00 | 14.40 | 36.98 | |||
| TTNP | 3.46 | 0.26 | 0.06 | -3.38 | 5.38 | 9.38 | 30.41 | |||
| SILO | 4.16 | 0.20 | 0.02 | 0.00 | 4.58 | 8.57 | 30.88 | |||
| CNSP | 3.84 | -1.51 | 0.00 | -2.97 | 0.00 | 5.53 | 32.96 | |||
| SXTP | 9.86 | 1.20 | 0.09 | 0.16 | 8.53 | 10.44 | 174.37 | |||
| XBIO | 3.92 | 0.74 | 0.15 | 0.70 | 4.09 | 11.68 | 27.98 | |||
| QLGN | 5.09 | -0.78 | 0.00 | 0.35 | 0.00 | 10.42 | 26.37 | |||
| SNGX | 3.00 | -0.17 | 0.00 | -0.23 | 0.00 | 5.22 | 22.54 |
Calidi Biotherapeutics Competitive Analysis
Calidi Biotherapeutics' competitive standing becomes clearer when measured alongside Clearmind Medicine, Can Fite, and Kazia Therapeutics. A 2.7 M market capitalization places Calidi Biotherapeutics firmly within this peer set. Calidi Biotherapeutics commands the larger valuation at 2.7 M versus 1.4 M. Can Fite holds the larger valuation at 15.2 M versus 2.7 M. Kazia Therapeutics holds the larger valuation at 84.8 M versus 2.7 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Calidi Biotherapeutics Competition Peer Performance Charts
How to Analyze Calidi Biotherapeutics Against Peers
Calidi Biotherapeutics' peer analysis compares Calidi Biotherapeutics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Calidi Biotherapeutics trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Calidi Biotherapeutics leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Calidi Biotherapeutics trades at a lower forward P/E than peers despite similar earnings growth, which may reflect differences in perceived risk or growth durability. Peer benchmarking can improve context for valuation without relying only on standalone multiples. For peer comparison, Calidi Biotherapeutics has a market cap of 2.69 M.
For Calidi Biotherapeutics, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist.